BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Real-time BOERSE MUENCHEN 16:46:32 05/07/2024 BST | ||
| 835.4 EUR | +0.01% |
|
| Current month | -0.16% | ||
| 1 month | +0.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 835.4 | +0.01% |
| 04/07/24 | 835.4 | -0.06% |
| 03/07/24 | 835.9 | +0.02% |
| 02/07/24 | 835.7 | -0.12% |
| 01/07/24 | 836.6 | -0.00% |
Real-time BOERSE MUENCHEN
Last update July 05, 2024 at 04:46 pm
More quotesStatic data
| Product type | Certificats Bonus |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CHB |
| ISIN | DE000HD0CHB6 |
| Date issued | 01/11/2023 |
| Strike | 850 kr |
| Maturity | 20/12/2024 (168 Days) |
| Parity | 1 : 1 |
| Emission price | 688.2 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 836.7 € |
|---|---|
| Lowest since issue | 658 € |
| Spread | 2.09 € |
| Spread % | 0.25% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Certificates
- Certificat
